- There is an increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (e.g., histoplasmosis) and infections due to other opportunistic pathogens. If these develop, discontinue the drug.
- Before starting treatment, perform a test for latent tuberculosis (TB); if positive, start treatment for TB prior to starting the drug. Monitor all patients for development of active TB during treatment, even if the initial latent TB test was negative.
- Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNFi’s.
Etanercept (Enbrel):8 Injection
Biosimilar(s): etanercept-szzs (Erelzi)9
Drug class: DMARD, TNFi
Boxed warning: *Refer to *ISI (above)| ← Previous | | | Next → | Single Page